These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Study of the critical points of HPMC hydrophilic matrices for controlled drug delivery. Miranda A, Millán M, Caraballo I. Int J Pharm; 2006 Mar 27; 311(1-2):75-81. PubMed ID: 16446063 [Abstract] [Full Text] [Related]
3. Estimation of the percolation thresholds in acyclovir hydrophilic matrix tablets. Fuertes I, Miranda A, Millán M, Caraballo I. Eur J Pharm Biopharm; 2006 Nov 27; 64(3):336-42. PubMed ID: 16876392 [Abstract] [Full Text] [Related]
5. Estimation of the percolation thresholds in ternary lobenzarit disodium-dextran-HPMC hydrophilic matrices tablets: effects of initial porosity. Castellanos Gil E, Iraizoz Colarte A, Bataille B, Brouillet F, Caraballo I. Eur J Pharm Sci; 2009 Nov 05; 38(4):312-9. PubMed ID: 19666114 [Abstract] [Full Text] [Related]
8. Study of the critical points and the role of the pores and viscosity in carbamazepine hydrophilic matrix tablets. Aguilar-de-Leyva A, Cifuentes C, Rajabi-Siahboomi AR, Caraballo I. Eur J Pharm Biopharm; 2012 Jan 05; 80(1):136-42. PubMed ID: 21946473 [Abstract] [Full Text] [Related]
10. Release behaviour of clozapine matrix pellets based on percolation theory. Aguilar-de-Leyva A, Sharkawi T, Bataille B, Baylac G, Caraballo I. Int J Pharm; 2011 Feb 14; 404(1-2):133-41. PubMed ID: 21094234 [Abstract] [Full Text] [Related]
12. Effect of drug particle size in ultrasound compacted tablets. Continuum percolation model approach. Millán M, Caraballo I. Int J Pharm; 2006 Mar 09; 310(1-2):168-74. PubMed ID: 16431046 [Abstract] [Full Text] [Related]
20. Oral controlled release formulations of rifampicin. Part II: Effect of formulation variables and process parameters on in vitro release. Hiremath PS, Saha RN. Drug Deliv; 2008 Jun 07; 15(3):159-68. PubMed ID: 18379928 [Abstract] [Full Text] [Related] Page: [Next] [New Search]